| Etoricoxib 30 mg | Etoricoxib 60 mg | Etoricoxib 90 mg | Diclofenac 150 mg |
---|---|---|---|---|
 | (N = 198) | (N = 102) | (N = 148) | (N = 102) |
 | n (%) | n (%) | n (%) | n (%) |
Clinical Adverse Experiences (AEs) | Â | Â | Â | Â |
   All Clinical AEs | 136 (68.7) | 73 (71.6) | 112 (75.7) | 81 (79.4) |
   Drug-related Clinical AEs†| 34 (17.2) | 18 (17.6) | 34 (23.0) | 25 (24.5) |
   Serious AEs | 12 (6.1) | 3 (2.9) | 5 (3.4) | 7 (6.9) |
   Discontinued due to an AE | 6 (3.0) | 6 (5.9) | 10 (6.8) | 12 (11.8) |
Most Common Clinical AEs * ‡ |  |  |  |  |
   Dizziness | 6 (3.0) | 6 (5.9) | 6 (4.1) | 1 (1.0) |
   Influenza-Like Disease | 14 (7.1) | 6 (5.9) | 4 (2.7) | 3 (2.9) |
   Upper Respiratory Infection | 32 (16.2) | 14 (13.7) | 28 (18.9) | 21 (20.6) |
   Diarrhea | 12 (6.1) | 1 (1.0) | 7 (4.7) | 13 (12.7) |
   Heartburn | 6 (3.0) | 5 (4.9) | 7 (4.7) | 6 (5.9) |
   Nausea | 8 (4.0) | 5 (4.9) | 4 (2.7) | 6 (5.9) |
   Headache | 10 (5.1) | 6 (5.9) | 1 (0.7) | 3 (2.9) |
   Urinary Tract Infection | 10 (5.1) | 3 (2.9) | 5 (3.4) | 5 (4.9) |
Gastrointestinal (GI) Nuisance Symptoms % | Â | Â | Â | Â |
   GI Nuisance Symptom AEs% | 26 (13.1) | 15 (14.7) | 20 (13.5) | 23 (22.5) |
Discontinuations | 0 (0.0) | 1 (1.0) | 2 (1.4) | 4 (4.0) |
Renovascular AEs | Â | Â | Â | Â |
   Lower Extremity Edema | 9 (4.5) | 4 (3.9) | 5 (3.4) | 2 (2.0) |
Discontinuations | 1 (0.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
   Congestive Heart failure | 0 (0.0) | 1 (1.3) | 0 (0.0) | 0 (0.0) |
Discontinuations | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
   Hypertension | 4 (2.0) | 3 (2.9) | 8 (5.4) | 5 (4.9) |
Discontinuations | 1 (0.7) | 0 (0.0) | 1 (0.8) | 1 (1.2) |